Collegium Paid $17 Million to Settle Nucynta ER Patent Dispute

Collegium Pharmaceutical, Inc. paid Grünenthal GmbH $17 million to settle a U.S. patent dispute over an authorized generic of Nucynta ER, ending the related license and its royalty payments. The companies signed the settlement on Oct. 15, and the license ended that day after Collegium made the payment. The agreement also resolves other claims between them. Grünenthal sued Collegium in federal court in New Jersey in February, alleging patent infringement connected to the launch of the authorized generic of Nucynta ER. Nucynta ER is an extended-release tapentadol pain medication. The U.S. license at issue was dated Jan. 13, 2015. Collegium assumed it in 2020 as part of its acquisition of Nucynta ER and Nucynta IR. The settlement discharged Collegium’s royalty obligations under that license.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.